Ximelagatran, an oral direct thrombin inhibitor, has a low potential for cytochrome P450-mediated drug-drug interactions.
about
Anticoagulation for non-valvular atrial aibrillation - towards a new beginning with ximelagatranDirect thrombin inhibitors: novel antithrombotics on the horizon in the thromboprophylactic management of atrial fibrillationDirect thrombin inhibitors: pharmacology and clinical relevance.Ximelagatran: the first oral direct thrombin inhibitor.Antithrombotic therapy in atrial fibrillation: ximelagatran, an oral direct thrombin inhibitor.Novel uses for current and future direct thrombin inhibitors: focus on ximelagatran and bivalirudin.Stroke Prevention in Atrial Fibrillation: Where are We Now?Ximelagatran, a new oral direct thrombin inhibitor, for the prevention of venous thromboembolic events in major elective orthopaedic surgery. Efficacy, safety and anaesthetic considerations.Ximelagatran: a new antithrombotic option in atrial fibrillation.Ximelagatran: an oral direct thrombin inhibitor.Ximelagatran: pharmacology, pharmacokinetics, and pharmacodynamics.New anticoagulants: beyond heparin, low-molecular-weight heparin and warfarinXimelagatran for stroke prevention in atrial fibrillation.A preliminary assessment of the critical differences between novel oral anticoagulants currently in development.The status of new anticoagulants.Ximelagatran for treatment and prophylaxis of recurrent events in deep vein thrombosis.The pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor, are unaffected by a single dose of alcohol.No pharmacokinetic or pharmacodynamic interaction between atorvastatin and the oral direct thrombin inhibitor ximelagatran.No pharmacokinetic or pharmacodynamic interaction between digoxin and the oral direct thrombin inhibitor ximelagatran in healthy volunteers.A pharmacokinetic study of the combined administration of amiodarone and ximelagatran, an oral direct thrombin inhibitor.
P2860
Q24807132-E8EBEEC1-6EE3-464E-B1B3-7F207E15E6FDQ28176666-008258E1-C975-4E9F-A120-6B3990324472Q33366516-1E74D51B-2120-4877-87CD-492AD8EC9C27Q35753482-2BB09683-8067-47C0-A9BD-B8EB4E184A04Q35777336-9AA1C298-986A-4F8B-9CC2-D151B2AF48E0Q35779232-45E81266-B868-450E-BDBA-58675CA74BFBQ35811581-60851C1C-58AC-4935-A9E5-93A9EC29E8D1Q35843864-FE38192E-7756-48E9-8F85-20B998E3C2A3Q35892171-19F83232-68F7-4AEA-B5DA-B6E006CAEB5DQ35895188-14063E83-C2A4-4607-A4D0-5DDD1B22361CQ35996015-4CC9D666-D8F1-40AE-B6A4-B3EBF37A3B9DQ36042279-BA595ACC-DA10-4BE0-A343-0A8146C66CBDQ36216784-3E485E0E-7A97-474D-89AE-FCA5F6727282Q36229356-6CD4C9F3-8F9D-4D14-BC55-0B1E95B28BAEQ36520745-7F19C046-6EF6-4328-836F-8084F66B0720Q36884659-A2F4DE3D-7CDE-4F69-BADA-DEC1245D990CQ44820370-17EDCB35-EBCA-4479-9B9F-2D09A3401738Q45001577-1382F00A-8090-40A2-A63C-F2DE0E10B86DQ45001580-808305D1-F197-486B-BC3E-47BFC21B9A97Q45022899-2FC6544B-1165-47A5-ACDA-DADC95110277
P2860
Ximelagatran, an oral direct thrombin inhibitor, has a low potential for cytochrome P450-mediated drug-drug interactions.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Ximelagatran, an oral direct t ...... diated drug-drug interactions.
@en
Ximelagatran, an oral direct t ...... diated drug-drug interactions.
@nl
type
label
Ximelagatran, an oral direct t ...... diated drug-drug interactions.
@en
Ximelagatran, an oral direct t ...... diated drug-drug interactions.
@nl
prefLabel
Ximelagatran, an oral direct t ...... diated drug-drug interactions.
@en
Ximelagatran, an oral direct t ...... diated drug-drug interactions.
@nl
P2093
P1476
Ximelagatran, an oral direct t ...... diated drug-drug interactions.
@en
P2093
Annelie Thuresson
Eva Bredberg
Lars Frison
Maria Eriksson-Lepkowska
Marita Larsson
Susanne Johansson
Tommy B Andersson
Ulf G Eriksson
P304
P356
10.2165/00003088-200342080-00005
P577
2003-01-01T00:00:00Z
P6179
1033664072